Flu vaccine lots that have been released by FDA and are available for distribution by the manufacturers.
Vaccine & Manufacturer Total number of Lots Released by FDA
AFLURIA
CSL Limited 22
Fluarix
GlaxoSmithKline Biologicals 5
FluLaval
ID Biomedical Corp. of Quebec 27
FluMist
MedImmune, LLC 14
Fluvirin
Novartis Vaccines and Diagnostics Limited 32
Fluzone
Sanofi Pasteur, Inc. 62
FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Bethesda, Maryland, on February 22, 2010, to select the influenza viruses for the composition of the influenza vaccine for the 2010-2011 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2009-2010 vaccines, and the availability of candidate strains and reagents.
The committee recommended that vaccines to be used in the 2010-2011 influenza season in the U.S. contain the following:
an A/California/7/09 (H1N1)-like virus; *
an A/Perth /16/2009 (H3N2)-like virus; **
a B/Brisbane/60/2008-like virus.***
The influenza vaccine composition to be used in the 2010-2011 influenza season in the U.S. is identical to that recommended by the World Health Organization on February 18, 2010, for the Northern Hemisphere's 2010-2011 influenza season.
*A/California/7/09 (H1N1)-like virus is the pandemic (H1N1) 2009 influenza virus. A monovalent vaccine containing this strain was made available to the United States in the fall of 2009.
**A/Perth/16/2009 (H3N2)-like virus is a change from the 2009-2010 influenza vaccine formulation.
***and B/Brisbane /60/2008-like virus is a current vaccine virus.
[Source: FDA]
